Predictors and Impact Of 30-Day Readmissions On Patient Outcomes and Healthcare Costs After Allogeneic Hematopoietic Cell Transplantation
Abraham S. Kanate(HonorHealth), Mehdi Hamadani(Medical College of Wisconsin), Londia Goff(West Virginia University), Sijin Wen(The University of Texas MD Anderson Cancer Center), Sonia Leadmon(West Virginia University), Kim Evans(Baylor College of Medicine), Michael Craig(Edith Cowan University), Jianjun Zhang, Aaron Cumpston(West Virginia University Hospitals), Quoc Van Truong(West Virginia University), Sherri Rauenzahn(West Virginia University)
Cited by 0
Related Papers
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
|Proceedings of the National Academy of Sciences|2007|517
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441